Logo
P

Providence Therapeutics

56 employees

Providence Therapeutics Holdings Inc is a clinical-stage biotechnology company focused on drug development and platform development. The Providence mRNA Medicines platform is comprised of four integrated platforms: 1) mRNA Medicines Platform, 2) NextGen lipid nanoparticles (LNP), 3) Manufacturing Platform and 4) Regulatory Platform. Providence’s mRNA and NextGen LNP platform offer an end-to-end solution for designing codon-optimized ultrapure mRNA that can be formulated in application optimized LNP. The Providence proprietary NextGen LNP, consists of rationally designed lipids that have been tested for suitability for programs in oncology, infectious diseases and gene delivery. Our scalable, efficient platform demonstrates differentiated capabilities in mRNA design, manufacturing, and formulation processes, as well as specific organ and tissue targeting. For more information, please visit providencetherapeutics.com Show more Show less

Investor insights

Funding rounds participated in

$2.1M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2015

Funding rounds raised

Total raised

$2.1M

from 1 investors over 1 rounds

P

Providence Therapeutics raised $2.1M on January 7, 2022

Investors: Bill & Melinda Gates Foundation

FAQ